ArticleThe Journal of infectious diseases2023
Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021.
Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Prevalence and epidemiology of hepatitis C in Uzbekistan: results from a population-based serosurvey, 2022.IJID regions · 2026Article
- Incidence of and Risk Factors for Tuberculosis Among Patients Treated for Hepatitis C: a Population-based Cohort Study.Open forum infectious diseases · 2026Article
- Results of the HCV self-testing implementation study through the secondary distribution of HCV self-tests among adult males in Georgia.BMC public health · 2026Observational
- Article
- Identifying and Linking to Care and Treatment Persons With Hepatitis C Who Were Lost to Follow-Up, Georgia 2023-2024.Journal of viral hepatitis · 2026Article
- Assessing the Seroprevalence of and Knowledge, Attitudes and Practices Related to Hepatitis B and Hepatitis C Among Dental Health Professionals in the Country of Georgia, 2023.Journal of viral hepatitis · 2026Article
- Awareness, knowledge, and practices related to hepatitis B and hepatitis C in the Republic of Uzbekistan-Results from a population-based survey, 2022.BMC public health · 2026Article
- Abnormal lipid profile in the context of liver steatosis measured by transient elastography: experiences from an outpatient endocrine clinic.Lipids in health and disease · 2026Article
- Primary liver cancer in Georgia: Seven years' experience following the launch of the Hepatitis C Elimination Program, 2015-2022.PloS one · 2026Article
- Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia.PLOS global public health · 2026Article
- Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co-Infection, Georgia, 2017-2023.Journal of viral hepatitis · 2025Article
- Temporal trends in hepatitis C incidence among people tested more than once in Georgia, 2017-23: a nationwide, retrospective cohort.The lancet. Gastroenterology & hepatology · 2025Article
- Prevalence of transfusion transmitted infections by mode of donation and remuneration status among blood donors in Georgia, 2018-2023.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2025Article
- Risk factors for HCV infection in Georgia: A case-control study.Journal of infection in developing countries · 2025Article
- Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.Journal of viral hepatitis · 2025Article
- Trends in new hepatitis C virus infections among repeat blood donors - Georgia, 2017-2023.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2025Article
- Article
- HIV and hepatitis C Virus in internally displaced people with and without injection drug use experience in the region of Shida Kartli, Georgia.BMC research notes · 2024Article
- Article
- Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015-April 2024.MMWR. Morbidity and mortality weekly report · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe country of Georgia initiated its hepatitis C virus (HCV) elimination program in 2015, at which point a serosurvey showed the adult prevalence of HCV antibody (anti-HCV) and HCV RNA to be 7.7% and 5.4%, respectively. This analysis reports hepatitis C results of a follow-up serosurvey conducted in 2021, and progress towards elimination.
methodsThe serosurvey used a stratified, multistage cluster design with systematic sampling to include adults and children (aged 5-17 years) providing consent (or assent with parental consent). Blood samples were tested for anti-HCV and if positive, HCV RNA. Weighted proportions and 95% confidence intervals (CI) were compared with 2015 age-adjusted estimates.
resultsOverall, 7237 adults and 1473 children were surveyed. Among adults, the prevalence of anti-HCV was 6.8% (95% CI, 5.9-7.7). The HCV RNA prevalence was 1.8% (95% CI, 1.3-2.4), representing a 67% reduction since 2015. HCV RNA prevalence decreased among those reporting risk factors of ever injecting drugs (51.1% to 17.8%), and ever receiving a blood transfusion (13.1% to 3.8%; both P < .001). No children tested positive for anti-HCV or HCV RNA.
conclusionsThese results demonstrate substantial progress made in Georgia since 2015. These findings can inform strategies to meet HCV elimination targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.